HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach.

Abstract
Bone marrow transplantation (BMT) performance can be limited by a lack of ideal donors, and the role of alternative donor hematopoietic cell transplantation in thalassemia is not well established. Here we used a new treatment protocol (Pc 26.1) in 16 thalassemia patients to perform BMT using phenotypically HLA-identical or 1-antigen-mismatched relatives (related donors [RDs]). We compared these results with HLA-matched sibling (matched sibling donors [MSDs]) BMT in 66 patients. The entire RD group and 88% of MSD group had sustained engraftment. Rejection incidence was 0% in the RD and 12% (95% confidence interval [95% CI], 6%-21%) in MSD groups (P = .15), with respective thalassemia-free survival probabilities of 94% (95% CI, 63%-99%) and 82% (95% CI, 70%-89%) (P = .24). Transplant-related mortality was 6% (95% CI, 1%-26%) in the RD group and 8% (95% CI, 3%-16%) in the MSD group (P = .83). The intensified new protocol was not associated with increased nonhematologic toxicity. The present data show that the Pc 26.1 preparative regimen allows thalassemia patients to safely undergo BMT from RDs who are not HLA-matched siblings, with transplant outcomes similar to patients with MSD grafts.
AuthorsJavid Gaziev, Marco Marziali, Antonella Isgrò, Pietro Sodani, Katia Paciaroni, Cristiano Gallucci, Marco Andreani, Manuela Testi, Gioia De Angelis, Cecilia Alfieri, Luisa Cardarelli, Michela Ribersani, Daniele Armiento, Guido Lucarelli
JournalBlood (Blood) Vol. 122 Issue 15 Pg. 2751-6 (Oct 10 2013) ISSN: 1528-0020 [Electronic] United States
PMID23963044 (Publication Type: Clinical Trial, Journal Article)
Topics
  • Adolescent
  • Amniotic Fluid
  • Bone Marrow Transplantation (methods, mortality)
  • Child
  • Child, Preschool
  • Family
  • Female
  • Graft Rejection (mortality)
  • Graft vs Host Disease (mortality)
  • Histocompatibility
  • Histocompatibility Testing
  • Humans
  • Infant
  • Male
  • Prospective Studies
  • Survival Rate
  • Thalassemia (mortality, therapy)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: